BC
Boxer Capital Portfolio holdings
AUM
$2.04B
1-Year Return
108.35%
This Quarter Return
-20.17%
1 Year Return
+108.35%
3 Year Return
+260.95%
5 Year Return
+1,103.68%
10 Year Return
–
AUM
$1.95B
AUM Growth
-$568M
(-23%)
Cap. Flow
+$92.5M
Cap. Flow
% of AUM
4.76%
Top 10 Holdings %
Top 10 Hldgs %
47.94%
Holding
79
New
8
Increased
5
Reduced
2
Closed
4
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
+$66.2M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$64.7M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$40.6M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
+$28.3M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$26.1M |
Top Sells
| 1 |
SPDR S&P Biotech ETF
XBI
|
+$135M |
| 2 |
ITOS
iTeos Therapeutics
ITOS
|
+$37.1M |
| 3 |
RACB
Research Alliance Corp. II Class A Common Stock
RACB
|
+$4.89M |
| 4 |
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
|
+$4.89M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$3.96M |
Sector Composition
| 1 | Healthcare | 96.15% |
| 2 | Financials | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Surrozen
SRZN
$99.1M
| – | – |
-13,333
| Closed | -$1.29M |
|
77
SPDR NYSE Technology ETF
XNTK
$1.33B
| – | – |
0
| – | – |
|
|
RACB
78
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| – | – |
-500,000
| Closed | -$4.89M |
|
|
JYAC
79
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| – | – |
-500,000
| Closed | -$4.89M |
|